ArticlePloS one2012
Predicting HLA class I non-permissive amino acid residues substitutions.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A comprehensive analysis of the IEDB MHC class-I automated benchmark.Briefings in bioinformatics · 2022Article
- Molecular mimicry between tumor associated antigens and microbiota-derived epitopes.Journal of translational medicine · 2022Article
- Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides.Journal of translational medicine · 2021Article
- Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy.Journal of translational medicine · 2021Article
- MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response.Frontiers in immunology · 2021Article
- Selecting Target Antigens for Cancer Vaccine Development.Vaccines · 2020Review
- Immunoinformatics and Vaccine Development: An Overview.ImmunoTargets and therapy · 2020Review
- HLA-A29 and Birdshot Uveitis: Further Down the Rabbit Hole.Frontiers in immunology · 2020Review
- Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients.Journal of translational medicine · 2018Article
- Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task.Bone marrow transplantation · 2016Article
- Key role of human leukocyte antigen in modulating human immunodeficiency virus progression: An overview of the possible applications.World journal of virology · 2015Review
- HLA-C Incompatibilities in Allogeneic Unrelated Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2014Review
- Immunoinformatic docking approach for the analysis of KIR3DL1/HLA-B interaction.BioMed research international · 2013Article
- MHC universal cells survive in an allogeneic environment after incompatible transplantation.BioMed research international · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Prediction of peptide binding to human leukocyte antigen (HLA) molecules is essential to a wide range of clinical entities from vaccine design to stem cell transplant compatibility. Here we present a new structure-based methodology that applies robust computational tools to model peptide-HLA (p-HLA) binding interactions. The method leverages the structural conservation observed in p-HLA complexes to significantly reduce the search space and calculate the system's binding free energy. This approach is benchmarked against existing p-HLA complexes and the prediction performance is measured against a library of experimentally validated peptides. The effect on binding activity across a large set of high-affinity peptides is used to investigate amino acid mismatches reported as high-risk factors in hematopoietic stem cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.